Media coverage about Abeona Therapeutics (NASDAQ:ABEO) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Abeona Therapeutics earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the company’s share price in the near future.

A number of research analysts have commented on the stock. FBR & Co reissued a “buy” rating on shares of Abeona Therapeutics in a research report on Friday, May 26th. Maxim Group set a $14.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Saturday, May 13th. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, June 6th. HC Wainwright set a $20.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 19th. Finally, Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Tuesday, July 11th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $17.86.

Abeona Therapeutics (NASDAQ:ABEO) traded up 2.48% during mid-day trading on Monday, hitting $8.25. 373,772 shares of the stock were exchanged. Abeona Therapeutics has a 12-month low of $3.43 and a 12-month high of $10.26. The company has a 50 day moving average of $7.44 and a 200 day moving average of $5.82. The firm’s market cap is $332.10 million.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. Abeona Therapeutics had a negative net margin of 2,568.57% and a negative return on equity of 26.99%. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.28 million. On average, equities analysts anticipate that Abeona Therapeutics will post ($0.57) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Abeona Therapeutics (NASDAQ:ABEO) Earns Daily News Impact Rating of 0.24” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/07/abeona-therapeutics-nasdaqabeo-earns-daily-news-impact-score-of-0-24-updated-updated-updated.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.